| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8528409 | Clinical Therapeutics | 2017 | 22 Pages |
Abstract
The effect of inhibiting PCSK9 with bococizumab on lipoprotein particle concentration and size are consistent with the general mechanism of PCSK9 inhibitors in blocking PCSK9-mediated downregulation of LDL receptors. PCSK9 inhibition has the potential to provide a clinical benefit through the modulation of atherogenic lipoprotein particles in addition to LDL-C lowering, and this effect will likely be assessed in future analyses of data from cardiovascular outcomes trials of PCSK9 monoclonal antibodies that are currently being conducted. ClinicalTrials.gov identifiers: NCT01243151, NCT01342211, and NCT01350141.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Hong PhD, Barry MD, Tenshang PhD, Tom BA, Chandrasekhar PhD, Philippe MSc, Pamela D. PhD,